Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of OC514 in Healthy Volunteers
NCT05264038Phase 1Completed
- Sponsor
- Oncocross
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OC514 in cancer cachexia (3 cohorts), sponsored by Oncocross. Primary endpoints: Treatment-emergent adverse events, Severity of TEAEs and 5 more. Started Mar 2022; status: completed.
02
Drugs
OC514
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT05264038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264038.